Teva’s Biaxin XL Generic Barred From Launch Pending May 26 Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
A temporary restraining order prevents Teva from launching its extended-release generic upon the May 23 expiration of the clarithromycin compound patent. Abbott already has gotten a jump on potential generic versions of immediate-release Biaxin with an “authorized” generic sold through Dava.